Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

294
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
294
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

880
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
880
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

1.1K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.1K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

515
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
515
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

289
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
289
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

2.9K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunotherapy-related interstitial lung disease: a call to improve risk stratification and diagnostic consistency.

ERJ open research·2026
Same author

Nintedanib in Post-COVID Interstitial Lung Disease: a double-blind, randomized, placebo-controlled Clinical Trial.

Annals of the American Thoracic Society·2026
Same author

Synergistic effects of metabolic syndrome and hazardous alcohol use on liver injury among Asian Americans.

Alcohol and alcoholism (Oxford, Oxfordshire)·2026
Same author

A single-center, observational, retrospective, case control study of rituximab for the treatment of interstitial pneumonia associated with autoimmune features.

Frontiers in pharmacology·2026
Same author

Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [<sup>177</sup>Lu]Lu-PSMA-617.

European urology·2025
Same author

Prescriber Specialty Involvement in Medicare Patients With Chronic Hepatitis B.

Journal of viral hepatitis·2025
Same journal

Anaphylaxis: State-of-the-Art.

Immunology and allergy clinics of North America·2026
Same journal

Upending Impending Doom.

Immunology and allergy clinics of North America·2026
Same journal

Mast Cell Activation Syndrome and Mimickers.

Immunology and allergy clinics of North America·2026
Same journal

Hereditary Alpha-Tryptasemia (HαT) as a Risk Modifier for Severe Anaphylaxis.

Immunology and allergy clinics of North America·2026
Same journal

Emerging Therapies for Anaphylaxis.

Immunology and allergy clinics of North America·2026
Same journal

Novel Epinephrine Delivery Devices.

Immunology and allergy clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Aug 2, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.0K

Drug-Induced Interstitial Lung Diseases.

Nicole Ng1, Maria L Padilla1, Philippe Camus2

  • 1Division of Pulmonary, Critical Care, and Sleep Medicine, Icahn School of Medicine at Mount Sinai, 1 Gustave L Levy Place, PO Box 1232, New York, NY 10029, USA.

Immunology and Allergy Clinics of North America
|April 13, 2023
PubMed
Summary
This summary is machine-generated.

Drug-induced interstitial lung disease (DI-ILD) is a growing concern, posing challenges in diagnosis and management. This review highlights key difficulties and the current clinical landscape of DI-ILD.

Keywords:
Chest imagingDrug-induced interstitial lung diseaseIatrogenicInfiltrative lung diseaseInterstitial lung diseaseLung toxicityPneumonitisPulmonary toxicityRespiratory system

More Related Videos

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

662
Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
07:10

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

Published on: May 20, 2019

13.7K

Related Experiment Videos

Last Updated: Aug 2, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.0K
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

662
Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
07:10

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

Published on: May 20, 2019

13.7K

Area of Science:

  • Pulmonology
  • Pharmacology
  • Toxicology

Background:

  • Drug-induced interstitial lung disease (DI-ILD) is an emerging cause of patient morbidity and mortality.
  • The expanding list of medications associated with DI-ILD complicates clinical recognition and research.
  • DI-ILD presents significant diagnostic and therapeutic hurdles.

Purpose of the Study:

  • To increase awareness of the complexities surrounding DI-ILD.
  • To discuss the current clinical challenges in managing DI-ILD.
  • To provide an overview of the existing clinical landscape for DI-ILD.

Main Methods:

  • Literature review of existing studies on DI-ILD.
  • Analysis of clinical case reports and pharmacological data.
  • Synthesis of current guidelines and expert opinions.

Main Results:

  • DI-ILD diagnosis is often delayed due to non-specific symptoms and varied drug associations.
  • Establishing definitive causality between a drug and ILD remains a significant challenge.
  • Management strategies for DI-ILD are not standardized and require individualized approaches.

Conclusions:

  • Heightened clinical suspicion and awareness are crucial for early DI-ILD detection.
  • Multidisciplinary collaboration is essential for effective DI-ILD diagnosis and patient care.
  • Further research is needed to improve diagnostic accuracy and therapeutic options for DI-ILD.